Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. - Wikidata - awgldk - TriplyDB

Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.

Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.

http://www.wikidata.org/entity/Q30516488

about

Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine Identifying the Role of E2 Domains on Alphavirus Neutralization and Protective Immune Responses Caribbean and La Réunion Chikungunya Virus Isolates Differ in Their Capacity To Induce Proinflammatory Th1 and NK Cell Responses and Acute Joint Pathology Expanding Regulatory T Cells Alleviates Chikungunya Virus-Induced Pathology in Mice Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy Envelope specific T cell responses & cytokine profiles in chikungunya patients hospitalized with different clinical presentations Prime-boost immunization strategies against Chikungunya virus A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis Nonhuman Primate Models of Chikungunya Virus Infection and Disease (CHIKV NHP Model)Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins Antigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease Fingolimod treatment abrogates chikungunya virus–induced arthralgia RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice Random codon re-encoding induces stable reduction of replicative fitness of Chikungunya virus in primate and mosquito cells Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques.A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice.Sero-prevalence and cross-reactivity of chikungunya virus specific anti-E2EP3 antibodies in arbovirus-infected patients Chikungunya virus infection results in higher and persistent viral replication in aged rhesus macaques due to defects in anti-viral immunity.Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response Identical strength of the T cell responses against E2, nsP1 and capsid CHIKV proteins in recovered and chronic patients after the epidemics of 2005-2006 in La Reunion Island.Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development.Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge.A Systematic Meta-analysis of Immune Signatures in Patients With Acute Chikungunya Virus Infection.Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.The neutralizing role of IgM during early Chikungunya virus infection Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis.Chikungunya virus and prospects for a vaccine.An essential role of antibodies in the control of Chikungunya virus infection.Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model.The Antiviral Alkaloid Berberine Reduces Chikungunya Virus-Induced Mitogen-Activated Protein Kinase Signaling.Virus infection drives IL-2 antibody complexes into pro-inflammatory agonists in mice.A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection.Global protein profiling studies of chikungunya virus infection identify different proteins but common biological processes.Chikungunya Virus Seroprevalence and Associated Factors among Hospital Attendees in Two States of Southwest Nigeria: A Preliminary Assessment.Immune-Mediated Protection and Pathogenesis of Chikungunya Virus.

P2860

Q24276414-4963B78C-5565-4705-8E8F-BB8CDF5BF589 Q24701741-92504772-624A-4F2C-B0A9-7BDAA2DFEB35 Q24701757-59C5C631-E65F-4506-9950-D9E04E1214B2 Q24701758-F0642335-2DC6-4CBD-9D02-AB23E22895EB Q24701766-582FCE95-4C50-4431-8756-94780435A599 Q24701768-15554939-70C9-4EAA-84B7-DCC97877FAF4 Q24701774-136D2FF5-D3C9-4D1F-8791-CAE09A4DD0AC Q26700129-AD22800F-F2A5-4CF3-8024-FF921A17A5B9 Q26782722-2B5F1784-6EBF-43BB-BE5B-86B9C1B54F04 Q27013018-3855FDF6-9C1D-414B-9519-FB5F89CEED23 Q27468808-D731B762-C1B5-463A-B995-8B8E1C25BCA7 Q28533408-E09DDC46-B3CC-4797-BE74-6B95BA5F0B1D Q28656413-0E3272F6-F775-4A31-B15A-F63E06B110E7 Q28804081-7D9847EC-2C82-4919-91D6-DE24BFEC001A Q30235512-AAA721A2-CA21-4234-A50D-FE216C741276 Q30938741-AC88A481-7064-4B9B-87D9-E53DC5BA1A55 Q31111619-4244DA03-EAC9-42C1-AE83-5D5292E7CCB8 Q33853893-6631210B-07E5-4482-A026-B4B0D0152E1A Q33945612-4D04EAEF-2611-458B-9E54-E2C5DCBAFDC4 Q34875480-78F45EAB-4207-464C-AD70-DC721DE42347 Q34927480-CCC70365-C74C-4FA0-B53E-C17E89556FDB Q35023852-4C82CAAC-56D9-4A02-AA74-5DA8D0C4BAF0 Q35078457-5C58AA50-9C33-4DF0-8297-F2AF95CF7853 Q35155037-2BE251C9-FD2B-46B6-B274-8CD9673600BB Q35238179-B9C3295E-9E32-4789-8B4A-827901D1AAD2 Q35641902-FCE83A25-46E8-4301-8B7A-25208511BA16 Q35850197-49632252-FF08-479E-8851-0B04D24F0F10 Q36275851-BB63A5B1-DD30-4D6B-A1AC-BF1EE0F0C053 Q36318652-03946E5F-1469-49DC-AD06-2A360B9AF40B Q36397446-47C06FB5-75BC-4DFB-A18F-C4AD52E23A3B Q36483436-156C85B1-04F8-4DB4-A4BB-04D7EA025DCB Q36582816-E0BF6C58-A97F-44B8-A52A-9B4C75D0B896 Q36914762-3FD988C9-A3DF-45DB-943F-A90F18E5879F Q37065242-14B1FE81-1B24-4838-B386-573D366EC085 Q37347319-C2D9C6D6-F366-446E-BF6C-53214D632424 Q37438906-CE283100-CB97-4F41-9022-CC24D344A900 Q37643733-B465FA7A-C873-439C-8211-4DF83646C131 Q38234431-577B5E65-6228-445B-9927-FA11ACA43DA4 Q38662416-7014B035-A005-488B-8327-0FA51976D562 Q39013750-3F5D3625-8338-4DC9-9149-05B3A620ACF7

P2860

Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.

http://www.wikidata.org/entity/Q30516488

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Early neutralizing IgG respons ...... pitope on the E2 glycoprotein.

@ast

Early neutralizing IgG respons ...... pitope on the E2 glycoprotein.

@en

type

label

Early neutralizing IgG respons ...... pitope on the E2 glycoprotein.

@ast

Early neutralizing IgG respons ...... pitope on the E2 glycoprotein.

@en

prefLabel

Early neutralizing IgG respons ...... pitope on the E2 glycoprotein.

@ast

Early neutralizing IgG respons ...... pitope on the E2 glycoprotein.

@en

P1433

Q30516488-778067A3-842B-4ABC-BB50-AC33F2D391A6

P1476

Q30516488-7CDBC0F0-3BD7-457F-B0ED-862DBE876C76

P2093

Q30516488-07401AAA-5238-47F5-8DFB-ECEBE3A5B55B

Q30516488-09C4DC1B-1DC1-4F48-B2AE-857060BD822F

Q30516488-10E10E78-F0E7-419B-8C9A-262C28AB4439

Q30516488-22C0C4D3-0E33-441C-8D75-F55CCE6EF29D

Q30516488-70B6A668-9775-4F22-A096-36DC6029E2EE

Q30516488-71CAAD49-E984-4565-9E9D-C0E8B765FA1E

Q30516488-73848952-6B2C-4C42-B5A3-8704E223CCAE

Q30516488-8505714A-EFD5-4E2B-B36B-4E6EBE7FFD78

Q30516488-A8C31AAA-8FED-44A4-B4DB-746C8E014B7C

Q30516488-D12968BF-CD4A-4E5E-A4D3-ADB2826F42A1

P2860

Q30516488-080F0263-A857-47C6-AA10-BF6D48F476DE

Q30516488-087F138A-835D-4D33-BFD3-C1A0B229C885

Q30516488-0A2114A4-8175-41AC-8FC7-E2772675764A

Q30516488-0A8B411B-EA14-432F-97DF-7186D2BEF36F

Q30516488-10BBCFF0-A036-4BC6-B12C-3637E6390CAA

Q30516488-20085154-9D55-409E-B465-DB1FA0C1E013

Q30516488-2157F2A2-1266-4433-938E-AED841F7B1B0

Q30516488-222C8C47-52DE-4BBA-89AA-035F703F1ACB

Q30516488-22A078D1-573A-477B-B441-DE0F08D7EA7E

Q30516488-23D9359B-9232-4DE2-A6A6-0CE52E77A9A1

P304

Q30516488-F9B81912-79CE-4D15-B786-60AD0A2C8AB3

P31

Q30516488-72D858E5-9030-4815-A77C-CF82A5320708

P356

Q30516488-5C1D78B9-0131-4274-875F-9435D8F5C5A9

P433

Q30516488-10400733-60F9-470D-BFE2-7C4E31B1774F

P478

Q30516488-1518DE51-66EA-42BC-9FA5-FFEEDB59CDCD

P50

Q30516488-3400C8B4-4D01-4C7A-8CD4-1849BA241D44

Q30516488-40820289-42D1-41AF-9919-A29DAC0095CB

Q30516488-41983C7A-523A-4FD4-9B37-0D245046BD30

Q30516488-43C8C26B-53FE-4F25-8E89-95A4DE3F7AD5

Q30516488-44565A09-0D91-4B2F-B839-ABAD856AED7E

Q30516488-66CE7A9E-9B0F-4697-8E8B-46FCD497D4D8

Q30516488-6CF283A0-FB04-481C-96D1-A0D68C3D15FD

Q30516488-85388BF5-424A-4366-BB18-FB318ED30751

Q30516488-E816CF44-48C5-41BF-B302-476ABB94B0C7

P5008

Q30516488-183EDCF4-5EF5-4FDD-965C-BB357C7C2FED

P577

Q30516488-828700BC-8600-49F0-A8FB-E749DCB1FBEA

P5875

Q30516488-73345401-C3DB-4BE0-AB5D-562D2AB85F16

P698

Q30516488-BFF3E5B0-EDF1-4A6F-A090-57A6D032C215

P921

Q30516488-56AD2106-3B0C-41FC-9E65-906E412E9FE7

P932

Q30516488-E006A187-A7B8-454B-927B-9100090C5709

P356

P1433

EMBO Molecular Medicine

P1476

Early neutralizing IgG respons ...... pitope on the E2 glycoprotein.

@en

P2093

Chong-Long Chua

http://www.w3.org/2001/XMLSchema#string

Diane Simarmata

http://www.w3.org/2001/XMLSchema#string

Jin-Kiat Wee

http://www.w3.org/2001/XMLSchema#string

Joo-Chuan Tong

http://www.w3.org/2001/XMLSchema#string

Karl-Heinz Wiesmüller

http://www.w3.org/2001/XMLSchema#string

Olaf Rötzschke

http://www.w3.org/2001/XMLSchema#string

Raymond T P Lin

http://www.w3.org/2001/XMLSchema#string

Roger Le Grand

http://www.w3.org/2001/XMLSchema#string

Sumitro Harjanto

http://www.w3.org/2001/XMLSchema#string

Wendy W L Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism

The use of nonhuman primate models in HIV vaccine development

Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160

Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages

A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection

Furin at the cutting edge: from protein traffic to embryogenesis and disease

IgG placental transfer in healthy and pathological pregnancies

Furin Processing and Proteolytic Activation of Semliki Forest Virus

Differential processing of sindbis virus glycoprotein PE2 in cultured vertebrate and arthropod cells

Multidisciplinary Prospective Study of Mother-to-Child Chikungunya Virus Infections on the Island of La Réunion

P304

330-343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EMMM.201200213

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2012-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221886967

http://www.w3.org/2001/XMLSchema#string

P698

22389221

http://www.w3.org/2001/XMLSchema#string

P921

Chikungunya virus

P932

3376860

http://www.w3.org/2001/XMLSchema#string